FBP News 5.32 First Bancorp (FBP)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
First Bancorp (FBP) 5.32 $FBP

Banking Stocks Technical Analysis -- Research on Popular, First BanCorp, East West Bancorp, and Bank of Ireland
PR Newswire - Tue Apr 15, 8:25AM CDT
On Monday, April 14, 2014, the NASDAQ Composite ended at 4,022.69, up 0.57%, the Dow Jones Industrial Average advanced 0.91%, to finish the day at 16,173.24, and the S&P 500 closed at 1,830.61, up 0.82%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Financials Sector Index closed the day at 289.10, up 0.79%, whereas the same has fallen by 1.43% in the last one month. Investor-Edge has initiated coverage on the following equities: Popular Inc. (NASDAQ: BPOP), First BanCorp. (NYSE: FBP), East West Bancorp Inc. (NASDAQ: EWBC) and Bank of Ireland (NYSE: IRE). Free technical research on BPOP, FBP, EWBC and IRE can be downloaded upon signing up at:

First BanCorp to Announce 1Q 2014 Results on April 24, 2014
Business Wire - Mon Apr 14, 11:08AM CDT
First BanCorp (the "Corporation" (NYSE:FBP), the bank holding company for FirstBank Puerto Rico, announced today that it expects to report its financial results for the first quarter ended March 31, 2014, after the close of market on Thursday, April 24, 2014.

Financial Sector Insight -- Research on Popular, First BanCorp., East West Bancorp, and HDFC Bank
PR Newswire - Wed Mar 26, 10:07AM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. The S&P 500 Financial Sector Index finished the day at 301.64, up 0.01%, and the same has gained 4.25% in the last one month. Investor-Edge has initiated coverage on the following equities: Popular Inc. (NASDAQ: BPOP), First BanCorp. (NYSE: FBP), East West Bancorp Inc. (NASDAQ: EWBC), and HDFC Bank Ltd (NYSE: HDB). Free technical research on BPOP, FBP, EWBC, and HDB can be downloaded upon signing up at:

First BanCorp. Announces Results for the Quarter and Year Ended December 31, 2013
Business Wire - Mon Feb 03, 4:04PM CST
--Net income of $14.8 million, compared to $15.9 million for the third quarter of 2013.

First BanCorp to Announce 4Q 2013 Results on February 3, 2014
Business Wire - Thu Jan 23, 6:06PM CST
First BanCorp (the "Corporation" (NYSE: FBP), the bank holding company for FirstBank Puerto Rico, announced today that it expects to report its financial results for the fourth quarter ended December 31, 2013, after the close of market on Monday, February 3, 2014.

NYSE stocks posting largest percentage increases
AP - Wed Jan 22, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:

M&T, 5 Other Banks Shine in Deep Data Dive
at The Street - Mon Dec 09, 9:37AM CST
A detailed analysis by Sterne Agee shows M&T's stock trading below historical valuations, while the company's core earnings performance has improved in a tough operating environment.

A Buying Opportunity for Puerto Rico Bank Stocks
at The Street - Mon Dec 02, 11:26AM CST
Key economic figures for the island territory could lead to an "over-reaction" to the downside for Puerto Rico bank stocks, according to KBW.

First Bancorp Shares Down 24.5% Since SmarTrend's Sell Call (FBP)
Comtex SmarTrend(R) - Tue Nov 05, 11:13AM CST
SmarTrend identified a Downtrend for First Bancorp (NYSE:FBP) on August 8th, 2013 at $7.40. In approximately 3 months, First Bancorp has returned 24.54% as of today's recent price of $5.58.

Shares of FBP Down 27.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 29, 9:51AM CDT
SmarTrend identified a Downtrend for First Bancorp (NYSE:FBP) on August 8th, 2013 at $7.40. In approximately 3 months, First Bancorp has returned 27.25% as of today's recent price of $5.38.

First BanCorp. Announces Earnings for the Quarter Ended September 30, 2013
Business Wire - Wed Oct 23, 7:00AM CDT
First BanCorp. (NYSE: FBP):

28.7% Return Seen to Date on SmarTrend First Bancorp Call (FBP)
Comtex SmarTrend(R) - Tue Oct 22, 9:23AM CDT
SmarTrend identified a Downtrend for First Bancorp (NYSE:FBP) on August 8th, 2013 at $7.40. In approximately 3 months, First Bancorp has returned 28.74% as of today's recent price of $5.27.

First Bancorp Has Returned 14.8% Since SmarTrend Recommendation (FBP)
Comtex SmarTrend(R) - Fri Sep 13, 9:30AM CDT
SmarTrend identified a Downtrend for First Bancorp (NYSE:FBP) on August 8th, 2013 at $7.40. In approximately 1 month, First Bancorp has returned 14.81% as of today's recent price of $6.30.

First Bancorp Shares Down 13.0% Since SmarTrend's Sell Call (FBP)
Comtex SmarTrend(R) - Wed Aug 28, 5:45PM CDT
SmarTrend identified a Downtrend for First Bancorp (NYSE:FBP) on August 8th, 2013 at $7.40. In approximately 3 weeks, First Bancorp has returned 13.05% as of today's recent price of $6.43.

Upgrade Alert for First Bancorp (FBP)
Comtex SmarTrend(R) - Wed Aug 14, 7:04AM CDT
First Bancorp (NYSE:FBP) was upgraded from Hold to Buy at Sandler O'Neill today. The stock closed yesterday at $6.63 on volume of 22.3 million shares, above average daily volume of 424,000. First Bancorp (NYSE:FBP) has potential upside of 11.2% based on a current price of $6.63 and analysts' consensus price target of $7.38. The stock should find resistance at its 50-day moving average (MA) of $7.37, as well as support at its 200-day MA of $5.79.

NYSE stocks posting largest volume increases
AP - Tue Aug 13, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:

Watch for First Bancorp to Potentially Rebound After Falling 2.93% Yesterday
Comtex SmarTrend(R) - Tue Aug 13, 4:52PM CDT
First Bancorp (NYSE:FBP) traded in a range yesterday that spanned from a low of $6.55 to a high of $6.86. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $6.75 on volume of 22.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 280

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 84

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 21

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 299

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 175

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 241

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 98

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Schouw & Co.'s Share Buy-Back Strategy for 2025

Updated Category News Views 153

Overview of Schouw & Co.'s Share Buy-Back Program Schouw & Co. has launched an exciting share buy-back initiative, aiming to enhance shareholder value significantly. This program began on May 5, 2025, and is designed to repurchase shares totaling up to DKK 120 million. This investment runs until December 31, 2025, reflecting the company's commitment to its shareholders....

Continue Reading
Schneider National Plans to Reveal Q3 2024 Earnings Soon

Updated Category News Views 45

Schneider National to Report Third Quarter 2024 Earnings Schneider National, Inc. (NYSE: SNDR), a leader in transportation and logistics services, has announced that it will release its third quarter 2024 earnings report on a future date, ahead of the market opening. This announcement is significant as it highlights the company’s continued focus on financial...

Continue Reading
A Closer Look at BioAge Labs: Legal Challenges Ahead

Updated Category News Views 206

Understanding the Legal Landscape of BioAge Labs Investors in BioAge Labs, Inc. have faced new uncertainties as the clinical-stage biopharmaceutical company becomes entangled in legal challenges. As the firm moves forward in its mission to develop innovative therapies aimed at combating metabolic diseases, significant developments have emerged that every investor should...

Continue Reading
Celebrating the Fusion of Science and Cinema at Starmus 2025

Updated Category News Views 202

Fusion of Science and Cinema at Starmus Festival The Starmus Festival is a unique event that intertwines science and art, culminating in extraordinary dialogues and presentations. Recently, renowned director Christopher Nolan was awarded the prestigious Stephen Hawking Medal for Science Communication during this remarkable celebration. This accolade is not just an honor...

Continue Reading
Millicom Takes Steps to Enhance Transparency in Holdings

Updated Category News Views 82

Millicom Takes Steps to Enhance Transparency in Holdings Millicom International Cellular S.A., commonly recognized as Tigo, is making significant strides in open communication and compliance by submitting regulatory notifications regarding major shareholder holdings. This initiative reinforces their commitment to transparency and regulatory excellence in the ever-evolving...

Continue Reading